Ticker: **EDIT**
Company: **Editas Medicine**
Sector: **Biotech / gene editing**
Current setup: **post-offering volatility**
Bias: **cautious bearish / fade setup if momentum fails**
Offering price: **$2.25**
Key level: **$3.50 warrant strike**
EDIT is on my watchlist after its public offering.
On May 26, Editas priced an underwritten public offering of **55,555,556 shares** plus accompanying warrants to purchase another **55,555,556 shares**. The share + warrant package was priced at **$2.25**.
Base gross proceeds are expected to be around **$125M** before expenses. If all warrants are exercised, EDIT could receive another **$194.4M**, bringing total potential gross proceeds up to **$319.4M**. The warrant exercise price is **$3.50**.
So the setup is simple:
This is bullish for the balance sheet, but bearish from a dilution / supply standpoint.
Fresh cash reduces near-term financing risk, but existing shareholders just got diluted, and the **$3.50 warrant strike** now becomes a major level to watch.
# The Close Was the Part That Caught My Eye
There were reportedly **over 1M shares dropped right at the close yesterday**.
I’m not calling that proof of anything shady. A large close print can be funds repositioning, offering-related hedging, traders selling the bounce, shorts pressing, or institutions using end-of-day liquidity to move size.
But for a short-term trade, it matters.
That was not just quiet retail noise. There was real size moving into the close, and that makes today’s price action around **$3.40–$3.50** even more important.
# Current Price
EDIT is trading in the low-$3 area after the offering news.
# Resistance Levels
* **$3.40–$3.50**: major post-offering resistance / warrant strike zone
* **$3.65**: next upside resistance
* **$4.00**: larger squeeze-risk level
# Support Levels
* **$2.90–$3.00**: near-term support
* **$2.75**: first downside target if momentum fades
* **$2.50**: deeper support
* **$2.25**: offering price / major reference level
# Signal
**Cautious bearish / fade watch**
I would not blindly short this just because there was an offering. A lot of the dilution may already be getting priced in.
The cleaner short setup is:
* Failed move into **$3.40–$3.50**
* Rejection near the warrant strike
* Weak volume on the bounce
* Break back under **$3.00**
# Trade Plan
Entry idea: failed bounce near **$3.40–$3.50**
Target 1: **$2.90–$3.00**
Target 2: **$2.75**
Stretch target: **$2.50**
Stop / invalidation: reclaim and hold above **$3.65–$3.75**
# Confidence
**55% bearish short-term**
Not a high-conviction short yet.
Post-offering biotech names can go two ways:
They can fade back toward the offering price, or they can squeeze because the financing removes near-term cash uncertainty.
# Reasons
🔴 Large equity-linked offering priced at **$2.25**.
🔴 Warrants at **$3.50** may create resistance or selling pressure near that level.
🔴 Existing shareholders are diluted.
🔴 Reported **1M+ shares dropped right at the close yesterday**, showing real size moving into the close.
🔴 If EDIT fails near $3.50, the setup favors a fade back toward $3.00 / $2.75.
🟢 Fresh cash improves the balance sheet and reduces immediate financing risk.
🟢 If buyers defend $3.00, shorts could get squeezed.
🟢 A strong biotech tape or positive pipeline update could change the setup fast.
# Bottom Line
EDIT is not an automatic short just because it raised money.
But after a large offering at **$2.25**, warrants struck at **$3.50**, and a reported **1M+ shares dropped right at yesterday’s close**, I’m watching the **$3.40–$3.50 zone** very closely.
If EDIT fails there, I think the post-offering bounce can fade.
My view: **cautious bearish short-term**
Best fade zone: **$3.40–$3.50**
Target: **$2.90–$3.00**, then **$2.75**
Invalidation: **hold above $3.65–$3.75**
Not financial advice. Just watching the post-offering setup.